Piper Jaffray Downgrades Salix Pharmaceuticals (SLXP) to Neutral Amid Takeover
Tweet Send to a Friend
Piper Jaffray downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Overweight to Neutral with a price target of $158.00 (from $160.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
